Performance of noninvasive fibrosis indices in chronic hepatitis B during pretreatment and post-treatment periods
BIOMARKERS IN MEDICINE, cilt.17, sa.19, ss.799-809, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 17 Sayı: 19
- Basım Tarihi: 2023
- Doi Numarası: 10.2217/bmm-2023-0405
- Dergi Adı: BIOMARKERS IN MEDICINE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
- Sayfa Sayıları: ss.799-809
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
Background: Pretreatment and post-treatment performances of noninvasive fibrosis indices were determined in patients with chronic hepatitis B. Method: This was a retrospective, single-center study. Results: The best area under the receiver operating characteristic curve values were detected for aspartate aminotransferase-to-alanine aminotransferase ratio (0.685) for >= F2, Fibrosis Index (FI; 0.703) for >= F3; FI (0.872) for >= F4 and FI (0.864) for cirrhosis. After antiviral treatment, the best area under the receiver operating characteristic curve values were detected in aspartate aminotransferase-to-alanine aminotransferase ratio (0.615) for >= F2; in FI based on four factors (FIB-4; 0.634) for >= F3; in FIB-4 (0.678) for >= F4 and in FIB-4 (0.814) for cirrhosis. Conclusion: FIB-4 and FI showed better performance in defining advanced fibrosis (>= F4) and cirrhosis. Ozdemir et al. demonstrate that the Fibrosis Index based on four factors and the Fibrosis Index showed better performance in defining advanced fibrosis (>= F4) and cirrhosis (>= F5) among noninvasive fibrosis indices including Aspartate Aminotransferase-to-Platelet Ratio Index, Fibrosis Index based on four factors, Aminotransferase-to-Alanine Aminotransferase Ratio and Fibrosis Index.